the aid library

ChAdOx1-S [recombinant], COVID-19 vaccine

World Health Organization WHO (2021) C_WHO

Manufacturers: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir... more

Download (144)

View PDF (191)

Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below. This document has been updat... more

AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine

World Health Organization WHO (2021) C_WHO

10 May 2021. Manufactureres: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto... more

Download (106)

View PDF (141)

Solidarity in response to the COVID-19 pandemic

Rahman-Shepherd, A.; C. Clift; E. Ross; et al. The Chatham House (2021) CC

Has the world worked together to tackle the coronavirus? July 2021. This research paper assesses how the global community has responded to calls for greater solidarity in tackling the COVID-19 pandemic, and presents the insights of key stakeholders and experts in global health governance, health sec... more

Therapeutics and COVID-19: living guideline (Arabic)
recommended

World Health Organization WHO (2022) C_WHO

3 March 2022 The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an ... more

Strategic Preparedness, Readiness and Response Plan to End the Global COVID-19 Emergency in 2022

World Health Organization WHO (2022) C_WHO

More than two years since the first SARS-CoV-2 infections were reported, the COVID-19 pandemic remains an acute global emergency. In this Strategic Preparedness, Readiness and Response plan for 2022, WHO sets out a number of key strategic adjustments that, if implemented rapidly and consistently at ... more

Download (264)

View PDF (136)

Fact sheet on Cervical Cancer

Cancer Association of South Africa (CANSA) (2021) CC

COVID-19 Scientific and Public Health Policy Update – (6 July 2022)

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.

Download (187)

View PDF (222)

Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, 20 December 2021

World Health Organization WHO (2022) C_WHO

27 September 2022 These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.

Download (182)

View PDF (214)

Innovative delivery systems for paediatric medicines

World Health Organization WHO; Unitaid (2020) C_WHO

Technology landscape

Download (239)

View PDF (214)

End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance

World Health Organization WHO (2022) C_WHO

his guidance provides interim guidance for the integration of SARS-CoV-2 and influenza virologic and genomic surveillance, from sentinel site case enrolment and sampling to the eventual sharing of the virus sequence data, a process known as end-to-end surveillance. This guidance builds on experience... more

Download (314)

View PDF (296)

Guidelines for the clinical management of severe illness from influenza virus infections

World Health Organization WHO (2022) C_WHO

Climate change and communicable diseases: a manual for health workers

World Health Organization. Regional Office for Europe (2011) C_WHO

There is a broad consensus nowadays that the Earth is warming up as a result of greenhouse gas emissions caused by anthropogenic activities. It is also clear that current trends in the fields of energy, development and population growth will lead to continuous and ever more dramatic climate change. ... more

Health in the Americas 2022: Overview of the Region of the Americas in the context of the COVID-19 pandemic

Pan American Health Organisation PAHO (2022) C_WHO

The objective of Health in the Americas: Overview of the Region of the Americas in the Context of the COVID-19 Pandemic is to respond to the need to address important public health issues in an increasingly timely manner, while serving as a platform with a close focus on specific issues of regional ... more

External Link

Taenia solium Use of existing diagnostic tools in public health programmes

World Health Organization WHO; Institutional Repository for Information Sharing iris (2022) C_WHO

Taeniasis and cysticercosis caused by the parasite T. solium affect vulnerable populations, mainly in Latin America, sub-Saharan Africa and Asia, where pigs (the intermediate host) roam free and poor sanitation allows pigs access to human faeces.

External Link

Treatment Guidelines for Antimicrobial Use in Common Syndromes

Indian Council of Medical Research - Department of Health Research (2017) C1

The publication of the of the Antimicrobial Treatment Guidelines represents the culmination of the efforts of the Antimicrobial Stewardship Program of ICMR to publish treatment guidelines for common syndromes in India. These guidelines are targeted for the health care settings. It aims to rationali... more

Download (163)

View PDF (199)

Drugs to prevent COVID-19: living guideline

World Health Organisation (WHO) (2023) C_WHO

The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform. Guidelines ... more

External Link

DNDi Strategic Plan 2021-2028 | DNDi - English version

DNDi - Drugs for neglected diseases initiative (2023) C2

Accessed on 04.04.2023 The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected patients

Field Guide for Preparedness and Response to Diphtheria Outbreaks in the Western Pacific Region

World Health Organization WHO (2023) C_WHO

Due to high routine vaccination coverage, overall counts of diphtheria case have significantly declined in the Western Pacific Region recently. However, diphtheria is still prevalent in several countries and areas of the Region and remains a public health issue due to its high case fatality rate. ... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Therapeutics and COVID-19: living guideline (Arabic) recommended

Therapeutics and COVID-19: living guideline (Arabic)
recommended